This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

ASCO '14: What's on Tap for Saturday

CHICAGO (TheStreet) -- I've landed in this great Midwestern city to attend and cover American Society of Clinical Oncology (ASCO) annual meeting. I'll be posting stories throughout the weekend and into Monday, so check my landing page on TheStreet for links. I'll be tweeting frequently from the ASCO data presentations, too, so follow me on Twitter at @adamfeuerstein.

I tend to keep my ASCO reporting schedule loose for maximum flexibility, but here's a rough idea of what you'll see and when from companies with a significant presence during Saturday's session.

ASCO media embargoes lift at 7:30 am ET on data from Eli Lilly's (LLY - Get Report) ramucirumab phase III study in non-small cell lung cancer (abstract no. LBA8006) and Pharmacyclics (PCYC) and Johnson & Johnson's (JNJ) phase III study comparing Imbruvica to Glaxo's (GSK) Arzerra in relapsed/refractory chronic lymphocytic leukemia. (The "RESONATE" study, abstract no. LBA7008.)

Both of these studies will be featured at an ASCO media briefing starting Saturday at 9 am ET. The actual Lilly ramucirumab data presentation at ASCO isn't until Monday, while Pharmacyclics' Imbruvica RESONATE data is presented on Tuesday. [Yes, this is confusing, but ASCO's data release policy can get funky at times.]

I'm skipping the ASCO media briefing Saturday morning to attend the dueling oral presentations for the competing T790-mutant lung cancer drugs from AstraZeneca (AZN - Get Report) and Clovis Oncology (CLVS) , respectively. Those presentations start at 9 am ET, I'll tweet as many slides from the presentations as I can. Much of the AstraZeneca data have been disclosed already, but we'll get a meaningful update on the Clovis drug tomorrow.

The other significant Saturday oral presentations features PD-1 immunotherapy data in kidney cancer from Bristol-Myers Squibb (BMY - Get Report). Those start at 4 pm ET. 

There is also a lung cancer poster session Saturday afternoon featuring data from Bristol, Ariad Pharma (ARIA) and Merrimack Pharma (MACK)

Karyopharm (KPTI - Get Report) has an oral presentation on selinexor data Saturday, as well.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.


Chart of I:DJI
DOW 17,830.76 -210.79 -1.17%
S&P 500 2,075.81 -19.34 -0.92%
NASDAQ 4,805.2910 -57.85 -1.19%

Adam's Tweets

Select the service that is right for you!

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Real Money Pro

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Trifecta Stocks

Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.

Product Features:
  • Model portfolio
  • Trade alerts
  • Recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Growth Seeker

Chris Versace, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.

Product Features:
  • Model portfolio
  • Small-cap and mid-cap focus
  • Intraday trade alerts
  • Weekly roundups
Daily Swing Trade

Master swing trader Alan Farley uses his sophisticated software screens to review thousands of stocks each day for you, to find just the handful that meet his demanding criteria.

Product Features:
  • Daily commentary and coaching on swing trading
  • Technical charts and analysis
Top Rated Stocks Top Rated Funds Top Rated ETFs